Chris Boshoff: The U.S. FDA has granted Fast Track designation for our investigational treatment for ER+/HER2- breast cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn:
“I’m pleased to share that the U.S. FDA has granted Fast Track designation for our investigational treatment for people with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.
There remains a significant need for additional treatment options for people with breast cancer whose disease has progressed. Pfizer is committed to driving innovation for these patients, and with our partner Arvinas, we look forward to continuing to advance this potentially important new therapy.
Learn more here.”
Proceed to the video attached to the post.
Source: Chris Boshoff/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023